Patents by Inventor Ritsuo Aiyama
Ritsuo Aiyama has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8697742Abstract: A breast cancer resistance protein (BCRP/ABCG2) inhibitor. The BCRP inhibitor contains, as an active ingredient, an acrylonitrile derivative or a salt thereof.Type: GrantFiled: March 29, 2006Date of Patent: April 15, 2014Assignee: Kabushiki Kaisha Yakult HonshaInventors: Ryuta Yamazaki, Yukiko Nishiyama, Tomio Furuta, Takeshi Matsuzaki, Hiroshi Hatano, Oh Yoshida, Masato Nagaoka, Ritsuo Aiyama, Shusuke Hashimoto, Yoshikazu Sugimoto
-
Patent number: 8101211Abstract: A composition for retarding skin aging which contains an edible herb medicine or medicines round in Taiwan, in particular a plant extract or extracts having melanin formation-unhibiting, elastase-inhibiting, hyaluronidase-inhibiting, active oxygen-eliminating and/or radical-capturing type antioxidant activities, and a medicinally acceptable base and/or additives for external dermal application. The composition is useful in promoting skin whitening effects, maintaining the tension and elasticity of the skin, facilitating skin moistening and providing the skin with anti-inflammatory and/or anti-allergic properties.Type: GrantFiled: December 10, 2001Date of Patent: January 24, 2012Assignee: Kabushiki Kaisha Yakult HonshaInventors: Katsuyoshi Chiba, Toshiro Sone, Kouji Miyazaki, Tomoko Hanamizu, Fukiko Nishisaka, Sachiko Matsumoto, Ritsuo Aiyama
-
Patent number: 7994186Abstract: A camptothecin-containing pharmaceutical composition which contains: (a) camptothecin or a derivative thereof, and (b) one or more compounds selected from among ascorbic acid or a salt thereof, sodium hydrogen sulfite, sodium sulfite, potassium pyrosulfite, sodium erythorbate, sodium thioglycolate, sodium pyrosulfite, and ?-thioglycerin. The pharmaceutical composition is useful in that, after storage for a long period of time or under light-irradiation conditions, camptothecin or a derivative thereof contained therein undergoes minimum degradation.Type: GrantFiled: April 18, 2005Date of Patent: August 9, 2011Assignee: Kabushiki Kaisha Yakult HonshaInventors: Masako Nakazawa, Ritsuo Aiyama, Masato Nagaoka
-
Publication number: 20100130525Abstract: An object of the invention is to provide a camptothecin compounds-containing aqueous pharmaceutical preparation which can be produced without heating and in which camptothecin compounds are dissolved in a stable state. The invention provides a camptothecin compound-containing aqueous pharmaceutical preparation, containing the following ingredients (a) to (c): (a) a camptothecin compound; (b) a phosphoric acid salt; and (c) phosphoric acid.Type: ApplicationFiled: July 26, 2006Publication date: May 27, 2010Applicant: KABUSHIKI KAISHA YAKULT HONSHAInventors: Masako Nakazawa, Ritsuo Aiyama
-
Publication number: 20090253656Abstract: The present invention is directed to a breast cancer resistance protein (BCRP/ABCG2) inhibitor. The BCRP inhibitor contains, as an active ingredient, an acrylonitrile derivative represented by formula (1): wherein one of R1 and R2 represents a cyano group and the other represents a hydrogen atom; Ar1 represents a group selected from among the groups represented by formulas (2) to (4): and Ar2 represents an aromatic hydrocarbon group having a condensed ring which may be substituted by a halogen atom, or a group selected from among the groups represented by the following formulas (5) to (15): or a salt thereof.Type: ApplicationFiled: March 29, 2006Publication date: October 8, 2009Applicant: Kabushiki Kaisha Yakult HonshaInventors: Ryuta Yamazaki, Yukiko Nishiyama, Tomio Furuta, Takeshi Matsuzaki, Hiroshi Hatano, Oh Yoshida, Masato Nagaoka, Ritsuo Aiyama, Shusuke Hashimoto, Yoshikazu Sugimoto
-
Publication number: 20080287374Abstract: The invention provides a cancer cell useful in screening BCRP-inhibitors, and a BCRP-inhibitor. The BCRP-inhibitor contains, as the active ingredient, a flavonoid represented by any of the following formulae (1), (2), (3), (4), and (5): and glycosides, esters, or salts thereof; and an anticancer agent containing the BCRP-inhibitor together with an anticancer agent available as the substrate of BCRP.Type: ApplicationFiled: July 29, 2008Publication date: November 20, 2008Applicant: KABUSHIKI KAISHA YAKULT HONSHAInventors: Ryuta YAMAZAKI, Yukiko Nishiyama, Tomio Furuta, Takeshi Matsuzaki, Hiroshi Hatano, Sachiko Matsumoto, Ritsuo Aiyama, Oh Yoshida, Masato Nagaoka, Shusuke Hashimoto, Yoshikazu Sugimoto
-
Publication number: 20080242691Abstract: An aqueous solution preparation containing camptothecins which does not require heating in its production, and wherein camptothecins have been solubilized in a stable manner is provided. The aqueous solution preparation containing camptothecins contains acetic acid and sodium acetate, and it has a pH of 2 to 5.Type: ApplicationFiled: February 9, 2005Publication date: October 2, 2008Applicant: KABUSHIKI KAISHA YAKULT HONSHAInventors: Masako Nakazawa, Ritsuo Aiyama
-
Patent number: 7371773Abstract: The invention provides a drug which inhibits BCRP. A breast cancer resistance protein inhibitor containing, as an active ingredient, a diphenylacrylonitrile derivative represented by the following formula (1): [wherein, each of 8 R's, which are the same or different from one another, represents a hydrogen atom, a hydroxyl group, a nitro group, an amino group, an acetylamino group (—NHCOCH3 group); a cyano group (—CN group); a formyl group (—CHO group), —COOR1 (R1 is hydrogen or C1-C4 alkyl), —O(CH2)nCOOR2 (n=1?7: R2 is hydrogen or C1-C4 alkyl), —OOCCH2CH2COOR3 (R3 is hydrogen, C1-C4 alkyl, (Z)-2-(3,4-dimethoxy-phenyl)-3-(4-hydroxy-phenyl)-acrylonitrile, or glycopyranosyl), a C1-C8 alkoxy group, a C1-C4 alkyl group, a halogen atom, a C1-C4 alkoxy C1-C4 alkoxy C1-C4 alkoxy group, a C2-C8 acyloxy group, a C2-C8 halogenoacyloxy group, a methylenedioxy group, a trifluoromethyl group, a phosphate group (i.e., —OP(O) (OH)2) or a salt thereof, a sulfate group (i.e.Type: GrantFiled: February 3, 2004Date of Patent: May 13, 2008Assignee: Kabushiki Kaisha Yakult HonshaInventors: Ryuta Yamazaki, Yukiko Nishiyama, Tomio Furuta, Takeshi Matsuzaki, Hiroshi Hatano, Oh Yoshida, Masato Nagaoka, Ritsuo Aiyama, Shusuke Hashimoto, Yoshikazu Sugimoto
-
Publication number: 20060235040Abstract: A camptothecin-containing pharmaceutical composition which contains: (a) camptothecin or a derivative thereof, and (b) one or more compounds selected from among ascorbic acid or a salt thereof, sodium hydrogen sulfite, sodium sulfite, potassium pyrosulfite, sodium erythorbate, sodium thioglycolate, sodium pyrosulfite, and ?-thioglycerin. The pharmaceutical composition is useful in that, after storage for a long period of time or under light-irradiation conditions, camptothecin or a derivative thereof contained therein undergoes minimum degradation.Type: ApplicationFiled: April 18, 2005Publication date: October 19, 2006Applicant: KABUSHIKI KAISHA YAKULT HONSHAInventors: Masako Nakazawa, Ritsuo Aiyama, Masato Nagaoka
-
Publication number: 20060135445Abstract: The invention provides a cancer cell useful in screening BCRP-inhibitors, and a BCRP-inhibitor. The BCRP-inhibitor contains, as the active ingredient, a flavonoid represented by any of the following formulae (1), (2), (3), (4), and (5): and glycosides, esters, or salts thereof; and an anticancer agent containing the BCRP-inhibitor together with an anticancer agent available as the substrate of BCRP.Type: ApplicationFiled: February 3, 2004Publication date: June 22, 2006Applicant: KABUSHIKI KAISHA YAKULT HONSHAInventors: Ryuta Yamazaki, Yukiko Nishiyama, Tomio Furuta, Takeshi Matsuzaki, Hiroshi Hatano, Sachiko Matsumoto, Ritsuo Aiyama, Oh Yoshida, Masato Nagaoka, Shusuke Hashimoto, Yoshikazu Sugimoto
-
Publication number: 20060128636Abstract: The invention provides a drug which inhibits BCRP. A breast cancer resistance protein inhibitor containing, as an active ingredient, a diphenylacrylonitrile derivative represented by the following formula (1): [wherein, each of 8 R's, which are the same or different from one another, represents a hydrogen atom, a hydroxyl group, a nitro group, an amino group, an acetylamino group (—NHCOCH3 group); a cyano group (—CN group); a formyl group (—CHO group), —COOR1 (R1 is hydrogen or C1-C4 alkyl), —O(CH2)nCOOR2 (n=1?7: R2 is hydrogen or C1-C4 alkyl), —OOCCH2CH2COOR3 (R3 is hydrogen, C1-C4 alkyl, (Z)-2-(3,4-dimethoxy-phenyl)-3-(4-hydroxy-phenyl)-acrylonitrile, or glycopyranosyl), a C1-C8 alkoxy group, a C1-C4 alkyl group, a halogen atom, a C1-C4 alkoxy C1-C4 alkoxy C1-C4 alkoxy group, a C2-C8 acyloxy group, a C2-C8 halogenoacyloxy group, a methylenedioxy group, a trifluoromethyl group, a phosphate group (i.e., —OP(O) (OH)2) or a salt thereof, a sulfate group (i.e.Type: ApplicationFiled: February 3, 2004Publication date: June 15, 2006Applicant: KABUSHIKI KAISHA YAKULT HONSHAInventors: Ryuta Yamazaki, Yukiko Nishiyama, Tomio Furuta, Takeshi Matsuzaki, Hiroshi Hatano, Oh Yoshida, Masato Nagaoka, Ritsuo Aiyama, Shusuke Hashimoto, Yoshikazu Sugimoto
-
Patent number: 7037536Abstract: The present invention relates to an ?-amylase activity inhibitor, and to food and beverages comprising the ?-amylase activity inhibitor. The ?-amylase activity inhibitor of the present invention exhibits remarkably excellent ?-amylase inhibitory activity as compared with guava extract. Accordingly, food and beverages containing the ?-amylase activity inhibitor are diet food and beverages suitable for people of high blood-sugar level or hyderlipidemia.Type: GrantFiled: March 9, 2001Date of Patent: May 2, 2006Assignee: Kabushiki Kaisha Yakult HonshaInventors: Takashi Makino, Ritsuo Aiyama, Yoriko Deguchi, Masaaki Watanuki, Masako Nakazawa, Harumi Mizukoshi, Masato Nagaoka, Katsuhisa Harada, Kuniko Osada
-
Publication number: 20040028643Abstract: The present invention concerns a composition for retarding skin aging which contains an edible herb medicine or medicines round in Taiwan, in particular a plant extract or extracts having melanine formation-unhibiting, elastase-inhibiting, hyaluronidase-inhibiting, active oxygen-eliminating and/or radical-capturing type antioxidant activities, and a medicinally acceptable base and/or additives for external dermal application. The composition is useful in promoting skin whitening effects, maintaining the tension and elasticity of the skin, facilitating skin moistening and providing the skin with anti-inflammatory and/or anti-allergic properties.Type: ApplicationFiled: June 10, 2003Publication date: February 12, 2004Inventors: Katsuyoshi Chiba, Toshiro Sone, Kouji Miyazaki, Tomoko Hanamizu, Fukiko Nishisaka, Sachiko Matsumoto, Ritsuo Aiyama
-
Publication number: 20030124208Abstract: The present invention relates to an &agr;-amylase activity inhibitor containing, as an effective component, polyphenols obtained through the following process: guava leaves and/or guava fruit are subjected to extraction with one or more solvents selected from among water and hydrophilic solvents; the resultant extract is subjected to ultrafiltration, to thereby remove substances having a molecular weight of less than 5,000; the remaining fraction is subjected to the butyl support hydrophobic chromatography. The elution (flow rate: 1 mL/min) of the sample was accomplished with the pH gradient by use of sodium dihydrogenphosphate and sodium phosphate solution (0.02 mol/L) and a fraction of the eluted substance is recovered, which fraction corresponds to the third single peak of an elution curve which is obtained when the absorbance of the substance is measured at 260 nm.Type: ApplicationFiled: November 14, 2002Publication date: July 3, 2003Inventors: Takashi Makino, Ritsuo Aiyama, Yoriko Deguchi, Masaaki Watanuki, Masako Nakazawa, Harumi Mizukoshi, Masato Nagaoka, Katsuhisa Harada, Kuniko Osada
-
Patent number: 5763673Abstract: A diarylheptanoide derivative of the following formula (1), ##STR1## and a drug composition comprising this compound, such as a 5-lipoxygenase inhibitor, an antiinflammatory agent, and the like. The diarylheptanoide derivative (1) is effective for treating and preventing various inflammatory diseases due to its strong 5-lipoxygenase inhibiting effect.Type: GrantFiled: November 22, 1995Date of Patent: June 9, 1998Assignee: Kabushiki Kaisha Yakult HonshaInventors: Ryuta Yamazaki, Takeshi Matsuzaki, Ritsuo Aiyama, Shusuke Hashimoto, Teruo Yokokura